Research programme: anticancer therapeutics and diagnostics - Biosceptre International

Drug Profile

Research programme: anticancer therapeutics and diagnostics - Biosceptre International

Alternative Names: BIL-03s; BIL-221s

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biosceptre International; Peptech
  • Developer Biosceptre International
  • Class Antibodies; Diagnostic agents; Imaging agents; Monoclonal antibodies
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Australia (Parenteral)
  • 31 May 2016 Biosceptre plans a phase I trial for of BIL 03s for Solid tumours in the United Kingdom
  • 13 Aug 2014 Preclinical development is ongoing in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top